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Problem
Previous studies have investigated the utility of inflammation markers
as predictors of preterm birth, but none have compared trends in levels
between uncomplicated and preterm pregnancy.
Method of study
We explored longitudinal changes in plasma cytokines, including IL-1b,
IL-6, IL-10, and TNF-a, as well as C-reactive protein in pregnant women
from a nested case–control study.
Results
IL-6 was associated with increased odds of spontaneous preterm birth,
defined by presentation of spontaneous preterm labor and/or preterm
premature rupture of the membranes. Associations were strongest later
in pregnancy. IL-10 was associated with increased odds of placentally
mediated preterm birth, defined by presentation with preeclampsia or
intrauterine growth restriction, and odds ratios were also highest near
the end of pregnancy.
Conclusion
Maternal inflammation markers were associated with increased risk of
preterm birth, and relationships differed by etiology of preterm delivery
and gestational age at sample collection.
Introduction
Preterm birth is a significant public health problem,
occurring in over 10% of births worldwide and con-
tributing largely to neonatal mortality and various
morbidities in childhood and later in life.1 Despite the
severity of this problem, most cases result from
unknown causes and mechanisms of preterm birth
remain poorly understood. This limits the ability to
predict and prevent preterm birth. Current interven-
tions are estimated to decrease the burden of preterm
birth rates only minimally over the next 5 years.2
Intrauterine inflammation at the maternal–fetal
interface is a well-established contributor to preterm
birth.3 The initial stages of this inflammation gener-
ally occur in an asymptomatic setting which has led
to intense investigation of biomarkers that may
identify those with an increased inflammatory bur-
den and thereby aid in the prediction of prematurity
risk. The most strongly predictive markers are from
matrices close to the maternal–fetal interface, such
as amniotic and cervicovaginal fluid.4 Plasma or
serum markers measured at various time points dur-
ing pregnancy have so far proven less useful.
Despite their lack of predictive value, a description
of profiles of systemic maternal inflammation mark-
ers over gestation may be important for a better
understanding of normal pregnancy and for
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characterizing mechanisms leading to preterm birth.
These profiles have not been well characterized to
date.
Previous studies characterizing longitudinal
changes in circulating maternal biomarkers have
been limited in sample size, number of time points
and repeated measures available, and have focused
on uncomplicated pregnancy. In the present study,
we analyzed the changes in levels of inflammatory
biomarkers, including cytokines IL-1b, IL-6, IL-10,
and TNF-a, and C-reactive protein (CRP) over the
course of normal pregnancy, and compare these
normal profiles to those from pregnant women who
delivered preterm.
Materials and methods
Study Population
This nested case–control study draws from a cohort of
over 1600 women who delivered at the Brigham and
Women’s Hospital in Boston between 2006 and
2008.5 Subjects were recruited early in pregnancy
(<15 weeks gestation) and provided demographic and
anthropometric information as well as urine and
blood samples at an initial visit (visit 1: median
gestational age [GA] = 9.71 weeks, range = 4.71–
16.1 weeks). Additional samples were collected,
processed, and stored for future use at up to three
subsequent visits: visit 2 (median GA = 17.9 weeks,
range = 14.9–21.9 weeks); visit 3 (median GA =
26.0 weeks, range = 22.9–29.3 weeks); and visit 4
(median GA = 35.1 weeks, range = 33.1–38.3 weeks).
For the present study, women who delivered live
singleton infants were selected and their samples
extracted from storage for measurement of biomar-
kers of inflammation. All women who delivered
preterm, at <37 weeks completed gestation, were
included (n = 130), as were 350 random controls.
Cases were examined overall as well as in subsets by
type, or etiology, of preterm birth.6 These groups
included (i) spontaneous preterm births, or those
preceded by preterm premature rupture of the mem-
branes (PPROM) and/or spontaneous preterm labor
(n = 56) and (ii) placental preterm births, those
resulting from preeclampsia or intrauterine growth
restriction (IUGR; <10th percentile in weight for
gestational age) during pregnancy (n = 35). Other
cases (n = 39) were medically indicated preterm
births, which resulted from other maternal or fetal
complications. This group was not examined in this
analysis, as there is no hypothesis regarding a unify-
ing biological mechanism for this set of cases.
Biomarker Analysis
A total of 1585 plasma samples (n = 391 for cases,
n = 1194 for controls) were analyzed for biomarkers
of inflammation at the University of Michigan Can-
cer Center Immunological Monitoring Core (Ann
Arbor, MI, USA). CRP was measured using a DuoSet
enzyme-linked immunosorbent assay (ELISA) (R&D
Systems, Minneapolis, MN, USA) with sensitivity to
10 pg/mL. Only one sample measured was below
the limit of detection (LOD) and was replaced with
the LOD/√2.7 One sample was above the upper limit
of detection (reported as >100 lg/mL) and was
replaced with 100 lg/mL. The distribution of CRP
levels was lognormal and all values were ln-trans-
formed for analysis.
Plasma samples were also analyzed for inflamma-
tory biomarkers IL-1b, IL-6, IL-10, and TNF-a using
the Milliplex MAP High Sensitivity Human Cytokine
Magnetic Bead Panel which allows for measurement
of multiple cytokines at once using a small sample
volume (EMD Millipore Corp., St. Charles, MO,
USA). We selected these cytokines because previous
studies of these cytokines in maternal blood were
most frequently associated with preterm birth, and/
or they have been strongly suggested as important
in the parturition process.8–10 Of the 1585 samples
analyzed, 176 were measured once and the remain-
ing were measured in duplicate. Correlation between
duplicates was high (Spearman R = 0.96–0.99). For
individual measures below the LOD (0.128 pg/mL
for all cytokines), values reported numerically were
kept as is, and values reported as <0.128 were
replaced with LOD/√2. Following these substitutions,
an arithmetic average of duplicate measures was cre-
ated for statistical analysis. As with CRP, all cytokine
levels were lognormally distributed and ln-trans-
formed.
Statistical Analysis
Analyses were performed using R version 2.15.2 2
(R Foundation for Statistical Computing, Vienna,
Austria) and SAS version 9.2 (SAS Institute Inc.,
Cary, NC, USA). We examined the distributions of
CRP and cytokine levels in all samples using geomet-
ric means and standard deviations as well as selected
percentiles. Spearman correlation coefficients were
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used to assess relationships between different bio-
markers in all samples measured in cases and con-
trols separately. To examine differences in biomarker
levels by demographic characteristics, we created
geometric means of biomarkers for each subject from
visits 1–3 to represent average exposure across preg-
nancy for each individual. Measures from visit 4
were excluded from this measure as some cases had
already delivered at that time point.5 Geometric
means of individual averages were calculated for cat-
egorical covariates, and differences for each level
were compared to the reference using a pairwise
T-test of ln-transformed values. We examined bio-
marker differences by the following categories: race/
ethnicity (White, African American, Other);
education level (high school, technical school, junior
college or some college, college graduate); health
insurance provider [private insurance/health mainte-
nance organization (HMO)/self-pay, Medicaid/sup-
plemental security income (SSI)/MassHealth]; body
mass index (BMI) at visit 1 (<25 kg/m2, 25 to
<30 kg/m2, >30 kg/m2); tobacco use (no smoking
during pregnancy, smoking during pregnancy);
alcohol use (alcohol use during pregnancy, no alco-
hol use during pregnancy); and parity (nulliparous,
parous).
To create estimates of differences in biomarkers
between cases and controls, we first used logistic
regression models to calculate odds of overall pre-
term birth as well as preterm birth subsets in associ-
ation with average exposure across pregnancy.
Initially, each biomarker was examined in relation
to preterm birth in its own model; however, we also
examined models with more than one biomarker
and with interaction terms in a secondary analysis.
Crude models were created without adjustment for
any covariates, and full models were built using a
forward stepwise procedure, in which covariates
examined in bivariate analysis were added one at a
time and included in final models if they changed
effect estimates by >10%. We also examined odds of
preterm birth in association with biomarker levels
from individual visits.
In addition to estimating associations, another aim
of our analysis was to describe variability and pat-
terns in inflammatory biomarker levels over preg-
nancy. First, we calculated intraclass correlation
coefficients (ICCs) from linear mixed effect models
with random intercepts only to estimate reproducibil-
ity of biomarker levels across pregnancy. ICC is
a ratio of between-individual to between-plus
within-individual variability and ranges from zero to
one, with a value of one representing perfect repro-
ducibility (i.e., zero within-individual variability).11
Second, we examined biomarker trajectories in asso-
ciation with GA using a generalized additive mixed
model framework (GAMM) with the mgcv package in
R.12 GAMM allows adjustment for correlation
between biomarker levels within subject using ran-
dom intercepts as well as random slopes. Covariates
included in the GAMM were the same as those used
in the logistic regression models. The association
between GA and biomarker levels was modeled by a
penalized regression spline term with maximum
allowable degrees of freedom = 10. Predicted values
of biomarker levels were extracted from GAMM
models using the predict function for reference
levels of covariates [maternal age = median (32.2),
race/ethnicity = white, education = High school
level, health insurance = Private/HMO/self-pay, BMI
<25 kg/m2] and were plotted with confidence inter-
vals. Models were created for: (i) controls alone; (ii)
controls and cases of spontaneous preterm birth, with
an interaction term between case status and the
smoothing term for GA; and (iii) controls and cases of
placental preterm birth, also with an interaction term
between case status and the smoothing term for GA.
Significant differences in levels between controls and
cases were evaluated by interaction terms.
Results
Most biomarkers were highly detectable in our pop-
ulation, with IL-6 detected in 97.9% of samples and
CRP, IL-10, and TNF-a detected in 99.9% of sam-
ples. IL-1b was slightly less detected, with only
78.0% of samples above the LOD. Geometric means,
standard deviations, and selected percentiles of bio-
markers in all samples are presented in Table I.
Spearman correlations between biomarkers are pre-
sented in Table II. While all correlations were statis-
tically significant, they were only weak to moderate
in strength. Correlations were similar between cases
and controls.
Distributions of demographic characteristics from
our study population are presented in Table III.
Women were predominantly white (59%), well-edu-
cated (68% junior college, some college, or college
graduate), and non-smokers (92%). Biomarker lev-
els showed some significant differences within
demographic groups, most clearly for CRP (Table III).
CRP levels were higher in African American
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compared to White mothers, in mothers with a high
school education only compared to mothers with a
college degree, in mothers with public compared to
private health insurance, in mothers who were over-
weight (BMI 25 to <30 kg/m2) or obese (BMI
>30 kg/m2) compared to normal weight pre-
pregnancy, and in mothers who were parous
compared to mothers who were nulliparous. Fewer
differences were observed by cytokine levels. No
significant differences in biomarker levels were
observed by tobacco or alcohol use during preg-
nancy, potentially due to the small number of alco-
hol (n = 19) and tobacco (n = 31) users in our study
population. By case status, the only significant dif-
ference observed in the crude comparisons was that
IL-6 concentrations were significantly higher in cases
compared to controls.
Some biomarkers levels were associated with
increased odds of preterm birth in the initial analysis
using geometric mean levels measured from visits 1–3
for each individual (Table IV). In unadjusted models,
IL-6 was associated with significantly increased odds
of overall preterm birth (odds ratio [OR] = 1.29, 95%
confidence interval [CI] = 1.09, 1.54). The association
became slightly stronger when spontaneous preterm
births were examined separately (OR = 1.33, 95%
CI = 1.07, 1.66) and remained in full models adjust-
ing for maternal age, race/ethnicity, education level,
health insurance provider, and BMI. An ln-unit
increase in IL-10 was also associated with increased
odds of overall preterm birth in adjusted models
(adjusted OR [AOR] = 1.28, 95% CI = 1.01, 1.62),
but this relationship appeared to be primarily driven
by the association with placental preterm births
(AOR = 1.67, 95% CI = 1.12, 2.49). Increased odds of
placental preterm birth were observed in association
with CRP and TNF-a in crude models, but in adjusted
models, the effect estimates were not statistically
significant. No significant associations were observed
for IL-1b.
We additionally created logistic models with multi-
ple biomarkers. For overall preterm birth, the most
elevated OR was in association with IL-6 and IL-10
levels. A model with both biomarkers indicated that
IL-6 was more strongly associated with overall pre-
term birth (AOR = 1.25, 95% CI = 0.98, 1.59) com-
pared to IL-10 (AOR = 1.07, 95% CI = 0.79, 1.45).
Similarly, in models of spontaneous preterm birth
when both IL-6 and IL-10 were included at once the
association between IL-10 and preterm birth was
diminished (AOR = 1.05, 95% CI = 0.70, 1.57) while
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the association with IL-6 remained stronger
(AOR = 1.30, 95% CI = 0.95, 1.78). Finally, for placen-
tal preterm birth, IL-6, IL-10, and TNF-a were all strong
predictors and we tested the effect of including all three
in one model. The results showed that the strongest
predictor was IL-10 (AOR = 1.64, 95% CI = 0.93, 2.91)
while the effect estimates for IL-6 (AOR = 0.92, 95%
CI = 0.58, 1.47) and TNF-a (AOR = 1.38, 95%
CI = 0.66, 2.88) were reduced. Interactions between
biomarkers were also examined but none were statisti-
cally significant (data not shown).
When associations between biomarkers and pre-
term birth were examined by individual visit, several
patterns emerged (Table V). For spontaneous preterm
birth, AOR was slightly larger in magnitude in associ-
ation with IL-6 levels at visits 2–4 (median GA 18–
25 weeks), although confidence intervals widened
due to smaller sample sizes. For placental preterm
birth, AOR in association with IL-6 levels was highest
at visit 4 (AOR = 1.90, 95% CI = 1.08, 3.34). IL-10
showed a slightly elevated AOR in association with
overall preterm birth at visit 3 (AOR = 1.36, 95%
CI = 1.05, 1.78) and similarly AOR of spontaneous
preterm birth at visits 2–4, although standard errors
were somewhat larger. AOR for placental preterm
birth in association with IL-10 levels was all signifi-
cant and increased steadily for visits 1–4. TNF-a
showed no association with overall preterm or spon-
taneous preterm birth, but, as with IL-10, was associ-
ated with steadily increasing AOR of placental
preterm birth from visits 1–4. Finally, we did not
observe associations between CRP or IL-1b and
preterm birth overall or by subtype when examined
by individual visit.
All cytokines measured showed excellent repro-
ducibility (ICC >0.75) across the duration of preg-
nancy (Table I). Temporal reliability for CRP was
slightly lower but reproducibility was still good (ICC
≥0.4 and <0.75).11 We next created GAMM models
to examine any patterns in biomarker levels over
pregnancy and to test for any differences in these
patterns in cases compared to controls. Models
included random intercepts and slopes as well as the
same set of covariates included in logistic models. In
controls alone, we found that CRP levels increased
early in pregnancy, peaked at approximately
20 weeks, and then gradually declined until the end
of pregnancy (Fig. 1). IL-6 levels had an opposite
trajectory, declining until approximately 20 weeks
gestation and then increasing toward the end of
pregnancy. IL-1b levels declined in a linear fashion
[estimated degrees of freedom (EDF) = 1], and TNF-
a levels remained somewhat level with slight
increases at 20 weeks and toward the end of gesta-
tion. Finally, IL-10 levels appeared to be unchanging
throughout the entire course of pregnancy (p for
smoothing term = 0.23, EDF = 1).
After examining patterns in controls alone, we
also examined and tested the difference in the rela-
tionship between GA and biomarker level by case
status using an interaction term. The first set of
models examined cases of spontaneous preterm birth
only. IL-6 levels were significantly different in spon-
taneous cases compared to controls (p for interac-
tion<0.001) and levels appeared to diverge as
pregnancy progressed (Fig. 2). IL-10 levels were sig-
nificantly different in cases of placental preterm
birth compared to controls (p for interaction = 0.02),
and the difference appeared to be linear across preg-
nancy (Fig. 3). Interaction terms for other cytokines
and CRP and spontaneous or placental preterm birth
were not statistically significant (data not shown).
Discussion
In the present study, we examined levels of inflam-
mation biomarkers, including CRP and cytokines, at
multiple time points during pregnancy in peripheral
blood plasma samples. We found that increases in
average levels of IL-6, IL-10, and TNF-a during preg-
nancy were associated with increased odds of overall
preterm birth. IL-6 was the strongest predictor in
spontaneous preterm pregnancies, and IL-10 was the
Table II Spearman Correlations between Biomarkers from All
Samples Measured in Cases (n = 379 Samples, 130 Subjects)
and Controls (n = 1143 Samples, 130 Subjects)
IL-1b IL-6 IL-10 TNF-a
Cases
CRP 0.06* 0.23* 0.12* 0.17*
IL-1b 0.40* 0.27* 0.21*
IL-6 0.61* 0.37*
IL-10 0.46*
Controls
CRP 0.09* 0.26* 0.05 0.18*
IL-1b 0.24* 0.10* 0.16*
IL-6 0.37* 0.25*
IL-10 0.31*
*Spearman correlation coefficient statistically significant
(P < 0.05).
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strongest predictor in placental preterm pregnancies.
Furthermore, we identified and depicted for the first
time longitudinal patterns in these biomarkers in
normal and preterm pregnancy and found differ-
ences in patterns by these groups.
Inflammation at the maternal–fetal interface is
one of most well-established causes of preterm
birth.3,13 Systemic or local infection can initiate a
cascade of events leading to premature parturi-
tion.8,13 Pro-inflammatory cytokines are the most
well studied in this pathway; however, reduced lev-
els of anti-inflammatory cytokines may be impor-
tant as well.14 Because of their well-known
involvement in this mechanism, a number of stud-
ies have measured cytokines in pregnant women in
an attempt to identify predictive clinical markers of
premature birth. Most of these studies have only
utilized measures from one time point during
Table III Distributions of Population Demographic Characteristics and Geometric Meansa of Inflammation Biomarkers within Groups
(n = 480)
Demographic characteristics n (%) CRP (lg/mL) IL-1b (pg/mL) IL-6 (pg/mL) IL-10 (pg/mL) TNF-a (pg/mL)
Race/ethnicity
White (reference) 281 (58.5) 5.20 0.34 1.40 13.3 2.91
African American 77 (16.0) 8.60* 0.23* 1.77 14.7 3.22
Other 122 (25.4) 6.20 0.28 1.61 15.1 2.99
Education
High school (reference) 68 (14.2) 7.68 0.24 1.73 15.5 3.26
Technical school 77 (16.0) 6.42 0.37* 1.91 16.6 3.07
Junior college or some college 138 (28.8) 6.43 0.28 1.75 14.2 2.98
College graduate 186 (38.8) 4.78* 0.33 1.19* 12.4 2.85
Missing 11 (2.29)
Health insurance
Private insurance/HMO/Self-pay (reference) 84 (17.5) 5.53 0.33 1.47 13.8 2.96
Medicaid/SSI/MassHealth 384 (80.0) 7.89* 0.23* 1.63 14.6 3.14
Missing 12 (2.50)
BMI at Visit 1
<25 kg/m2 (reference) 249 (51.9) 4.08 0.32 1.24 13.8 2.89
25 to <30 kg/m2 126 (26.3) 6.47* 0.31 1.78* 14.7 2.78
>30 kg/m2 101 (21.0) 13.1* 0.28 1.90* 13.1 3.47*
Missing 4 (0.83)
Tobacco use
Smoked during pregnancy (reference) 31 (6.46) 7.95 0.23 1.54 13.8 3.17
No smoking during pregnancy 443 (92.3) 5.80 0.31 1.52 14.0 2.97
Missing 6 (1.25)
Alcohol use
Alcohol use during pregnancy (reference) 19 (3.96) 5.35 0.39 1.07 12.4 2.56
No alcohol use during pregnancy 451 (94.0) 5.94 0.30 1.54 14.0 3.00
Missing 10 (2.08)
Parity
Nulliparous (reference) 215 (44.8) 5.36 0.30 1.48 13.6 2.87
Parous 265 (55.2) 6.38* 0.30 1.53 14.3 3.07
Infant gender
Male (reference) 212 (44.2) 6.41 0.30 1.60 13.5 2.97
Female 268 (55.8) 5.52 0.30 1.44 14.4 2.99
Pretermb
<37 weeks (reference) 130 (27.1) 6.52 0.30 1.94 15.9 3.15
≥37 weeks 350 (72.9) 5.68 0.30 1.37* 13.3 2.92
aGeometric means for each category were created from subject-specific averages (geometric means from levels measured at up to three
time points per individual). bThe large proportion of preterm cases is attributable to the case–control study design and is not indicative of
prevalence in the baseline population. *Denotes significant difference in biomarker concentration from reference category based on pairwise
T test (P < 0.05).
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pregnancy, and previous results have been conflict-
ing for the cytokines examined in the present
study.4,15 Of the pro-inflammatory cytokines we
measured, plasma IL-6 concentrations have been
associated with increased odds of preterm birth in
the largest number of studies, although results from
a recent meta-analysis did not show a significant
association.4 In several studies, lower IL-10 levels
have been associated with increased risk of preterm
birth, which may be expected as IL-10 is anti-
inflammatory; however, other studies have reported
null associations.16–19 Our results showed a positive
association between IL-10 and odds of preterm
birth, which may indicate that IL-10 is also a bio-
marker of inflammation because of a normal physi-
ologic anti-inflammatory response to an
inflammatory state. This hypothesis is supported by
the positive correlation between IL-6 and IL-10
observed in this study as well.
While not directly involved in the parturition
mechanism, CRP is a strong marker of overall
inflammation and systemic maternal levels may indi-
cate changes that would be otherwise difficult to
detect.20 Hence, CRP levels in peripheral blood have
been the focus of a similarly large number of studies.
However, as with cytokines, a number of positive
associations with preterm birth have been observed
but predictability is low.4
Fewer studies have examined longitudinal
changes in peripheral cytokines or CRP during
pregnancy, and most of these in normal pregnan-
cies only. A 2007 study with a large number of
subjects (n = 707) examined differences in cytokine
levels during early and mid-pregnancy.21 IL-6 levels
were notably higher later in pregnancy and no
change in TNF-a was observed. Another study with
a small number of subjects (n = 20 with three time
points) examined changes in IL-6 and TNF-a over
pregnancy and also observed that IL-6 levels
increased across gestation but that there was no
change in TNF-a levels.22 Our findings in control
subjects are somewhat consistent with these results,
as we observed increases in IL-6, but we also
observed increases in TNF-a levels later in preg-
nancy. Additionally, we observed decreases in IL-1b
across gestation which has not been previously
reported. Two other studies with fewer subjects but
a larger number of repeated measurements
observed no changes in pro-inflammatory cytokines
during pregnancy.23,24 Another study examined a
panel of cytokines measured in maternal peripheral
blood three times during pregnancy and twice
Table IV Unadjusted and Adjusteda Odds Ratios (95% Confidence Intervals) of Preterm Birth in Association with Ln-Unit Increase in Averageb
Inflammation Marker Concentration
n (cases, controls)
Unadjusted OR (95%CI)
Overall preterm Spontaneous preterm Placental preterm
130, 350 56, 350 35, 350
CRP 1.16 (0.94, 1.43) 1.16 (0.86, 1.58) 1.57 (1.08, 2.28)*
IL-1b 1.03 (0.87, 1.23) 1.06 (0.83, 1.34) 1.01 (0.74, 1.38)
IL-6 1.29 (1.09, 1.54)* 1.33 (1.07, 1.66)* 1.30 (0.98, 1.71)
IL-10 1.24 (0.99, 1.54) 1.33 (1.00, 1.78) 1.38 (0.98, 1.92)
TNF-a 1.25 (0.88, 1.78) 1.14 (0.70, 1.86) 2.32 (1.24, 4.33)*
n (cases, controls)
Adjusted OR (95%CI)
Overall preterm Spontaneous preterm Placental preterm
127, 332 56, 332 33, 332
CRP 1.07 (0.84, 1.37) 1.23 (0.86, 1.75) 1.03 (0.66, 1.60)
IL-1b 1.00 (0.83, 1.20) 1.02 (0.79, 1.30) 1.04 (0.73, 1.47)
IL-6 1.29 (1.07, 1.56)* 1.33 (1.05, 1.68)* 1.29 (0.90, 1.84)
IL-10 1.28 (1.01, 1.62)* 1.31 (0.97, 1.78) 1.67 (1.12, 2.49)*
TNF-a 1.16 (0.81, 1.66) 1.12 (0.69, 1.82) 1.83 (0.92, 3.61)
*Significantly elevated OR (P < 0.05).
aFull models adjusted for maternal age, race/ethnicity, education, health insurance provider, and body mass index (BMI) at visit 1.
bOR calculated in association with subject-specific averages (geometric means from levels measured at up to three time points per individ-
ual).
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postpartum but focused analysis on differences in
levels pre- versus post-delivery (n = 50).25
Several studies have examined IL-10 levels longi-
tudinally during normal pregnancy. Holmes et al.9
observed that pregnant women had higher levels
compared to non-pregnant women at up to three
time points during gestation, but there was no differ-
ence by timing of measurement. Another study
found no changes in IL-10 expression across normal
pregnancy in peripheral blood samples.23 Our results
were consistent with these findings, as levels of IL-
10 were unchanging in controls throughout the
duration of pregnancy. However, our findings con-
trasted with those from a recent study in which
increased LPS-stimulated peripheral blood mononu-
clear leukocyte IL-10 levels were observed at 25–28
compared to 16–22 weeks gestation in women who
delivered preterm (35–36 weeks) compared to term,
although results from that study may have been
affected by use of a study population in which all
women had previously had a preterm birth.18
Finally, few studies have examined changes in
CRP levels across gestation. In 1990, Nielsen and col-
leagues examined CRP levels in 60 pregnant women
from 4 to 10 time points.26 They reported that mea-
sures were randomly distributed across pregnancy,
but no additional statistical techniques were utilized
to examine changes. In our analysis, we observed
for the first time an increase in CRP levels early in
pregnancy up to approximately 20 weeks gestation,
followed by a decline in later pregnancy in women
who went on to deliver at term. Two other small
studies with 2–3 measurements during pregnancy
observed no change in serum levels across gesta-
tion.22,27
We were only able to identify one study that
examined changes in inflammation biomarkers across
non-normal pregnancy, focusing on preeclamptic
Table V Adjusteda Odds Ratios (95% Confidence Intervals) of Preterm Birth in Association with Ln-Unit Increase in Inflammation Marker
Concentration at Individual Visits
n (cases, controls)
Overall preterm birth
Visit 1 Visit 2 Visit 3 Visit 4
114, 283 107, 282 100, 273 61, 299
CRP 1.04 (0.83, 1.29) 1.10 (0.86, 1.40) 0.94 (0.74, 1.20) 0.95 (0.71, 1.28)
IL-1b 1.03 (0.86, 1.23) 0.97 (0.80, 1.17) 1.05 (0.87, 1.26) 1.04 (0.83, 1.29)
IL-6 1.22 (1.02, 1.45)* 1.29 (1.06, 1.56)* 1.25 (1.01, 1.55)* 1.21 (0.93, 1.56)
IL-10 1.17 (0.94, 1.46) 1.26 (0.98, 1.60) 1.36 (1.05, 1.78)* 1.08 (0.80, 1.46)
TNF-a 1.08 (0.77, 1.53) 1.13 (0.78, 1.64) 1.17 (0.79, 1.73) 1.23 (0.78, 1.95)
n (cases, controls)
Spontaneous preterm birth
Visit 1 Visit 2 Visit 3 Visit 4
50, 283 50, 282 43, 273 21, 299
CRP 1.11 (0.82, 1.50) 1.31 (0.93, 1.83) 0.86 (0.62, 1.19) 1.07 (0.64, 1.77)
IL-1b 1.03 (0.81, 1.31) 1.05 (0.82, 1.34) 1.08 (0.84, 1.39) 0.99 (0.71, 1.39)
IL-6 1.21 (0.97, 1.52) 1.39 (1.10, 1.77)* 1.35 (1.01, 1.79)* 1.41 (0.98, 2.04)
IL-10 1.18 (0.88, 1.58) 1.34 (0.98, 1.83) 1.35 (0.96, 1.92) 1.27 (0.80, 1.99)
TNF-a 1.05 (0.66, 1.68) 1.12 (0.69, 1.84) 0.97 (0.57, 1.64) 1.32 (0.65, 2.68)
n (cases, controls)
Placental preterm birth
Visit 1 Visit 2 Visit 3 Visit 4
32, 283 28, 282 29, 273 13, 299
CRP 1.07 (0.74, 1.55) 0.98 (0.62, 1.53) 0.92 (0.58, 1.48) 1.02 (0.56, 1.86)
IL-1b 1.10 (0.80, 1.52) 0.97 (0.68, 1.39) 1.22 (0.87, 1.73) 1.27 (0.82, 1.98)
IL-6 1.27 (0.92, 1.75) 1.35 (0.94, 1.93) 1.22 (0.81, 1.81) 1.90 (1.08, 3.34)*
IL-10 1.51 (1.04, 2.20)* 1.63 (1.09, 2.45)* 2.03 (1.30, 3.16)* 2.66 (1.41, 5.03)*
TNF-a 1.86 (0.97, 3.53) 1.74 (0.87, 3.48) 2.15 (1.03, 4.50)* 2.41 (0.86, 6.71)
*Significantly elevated OR (P < 0.05).
aFull models adjusted for maternal age, race/ethnicity, education, health insurance provider, and body mass index (BMI) at visit 1.
American Journal of Reproductive Immunology 72 (2014) 326–336
ª 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd 333
LONGITUDINAL INFLAMMATORY MARKERS AND PREMATURITY
women.24 As far as we are aware, our study is the
first to examine changes in plasma cytokine and CRP
levels during pregnancy from women who later deli-
ver preterm. IL-6 levels across pregnancy were signif-
icantly different in spontaneous preterm cases
compared to controls based on GAMMs, and levels
appeared to diverge between the two groups as preg-
nancy progressed. A similar pattern was observed for
IL-10 levels in placental preterm cases compared to
controls.
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Fig. 1 Plasma Inflammation biomarker levels by gestational age (GA) at sample collection in mothers with term delivery. Levels predicted from
smooth term for GA from generalized additive mixed models for subjects with baseline levels for model covariates, including maternal age (32.2),
race/ethnicity (white), education level (High School), health insurance provider (Private health insurance/HMO/self-pay), and body mass index
(<25 kg/m2) at visit 1. n = 1135 observations; n = 282 subjects.
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Fig. 2 Plasma IL-6 levels by gestational age (GA) at sample collection
in mothers with spontaneous preterm (dashed) compared to term
(solid) delivery. Levels predicted from smooth term for GA from
generalized additive mixed models for subjects with baseline levels
for model covariates, including maternal age (32.2), race/ethnicity
(white), education level (High School), health insurance provider
(Private health insurance/HMO/self-pay), and body mass index (<25 kg/
m2) at visit 1. n (cases) = 161 observations, 50 subjects; n
(controls) = 1087 observations, 282 subjects.
Cases (placental)
Controls
GA at sample collection (Weeks)
IL
-1
0 
(p
g/
m
L)
5 10 15 20 25 30 35
0
10
20
30
40
P(interaction) = 0.02
Fig. 3 Plasma IL-10 levels by gestational age (GA) at sample
collection in mothers with placental preterm (dashed) compared to
term (solid) delivery. Levels predicted from smooth term for GA from
generalized additive mixed models for subjects with baseline levels
for model covariates, including maternal age (32.2), race/ethnicity
(white), education level (High School), health insurance provider
(Private health insurance/HMO/self-pay), and body mass index (<25 kg/
m2) at visit 1. n (cases) = 98 observations, 32 subjects; n
(controls) = 1087 observations, 282 subjects.
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Our results indicate that the biomarkers measured
have moderate to high reproducibility throughout
pregnancy. This suggests that (i) measuring levels at
multiple time points during pregnancy may not be
more useful than a single measurement for predict-
ing preterm birth and (ii) changes observed across
gestation are subtle. While it has been reported that
peripheral markers may not be useful for predictive
purposes, measuring the longitudinal changes over
pregnancy may be useful for several reasons. First,
these patterns may be helpful for understanding the
mechanisms underlying different types of preterm
birth. In mothers who went on to have a spontane-
ous preterm birth, it is notable that while IL-6
increased toward the end of pregnancy, there were
no significant differences in cases compared to con-
trols for TNF-a or IL-1b levels. In mothers with pla-
cental preterm birth, IL-10 levels were significantly
higher across gestation, and levels measured at the
end of pregnancy differed most in cases compared to
controls. As placental preterm birth is typically char-
acterized by syncytial knot formation and placental
infarction occurring at the beginning of pregnancy,6
these stronger findings in association with levels
measured toward the end of pregnancy are different
from what we would expect. Future investigation of
this relationship could be important for better
understanding the mechanism for the relationship
between placentation and preterm birth.
These curves may also be used for the identification
of internal or external factors contributing to pre-
maturity. We have established that changes in the IL-
6 and IL-10 profiles during pregnancy are associated
with spontaneous and placental preterm birth,
respectively. However, an interesting next step will
be to explore through cellular or epidemiology studies
what upstream factors could be causing these shifts.
Our study was limited by the availability of plasma
samples only; using other matrices for cytokine and
CRP measurement, particularly those at the mater-
nal–fetal interface, such as amniotic or cervicovaginal
fluid, may be more representative of physiologic
changes relevant to pregnancy maintenance.4 How-
ever, collection of a large number of these samples
across gestation may not be feasible or ethical for an
exploratory study. Despite this limitation, our study
has many strengths. It utilized one of the larger popu-
lations to date, by number of women and by number
of samples per woman, to examine the longitudinal
changes in cytokine and CRP levels over pregnancy.
We used advanced statistical modeling techniques to
explore these nuanced changes and test for differ-
ences in those changes in women who delivered pre-
term compared to term, which has not been done
previously. These results provide novel and useful
data for future investigation of mechanisms and
causes of preterm birth.
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